Enormous progress has been made in identifying ligands for G protein--coupled receptors (GPCRs) since the 5HT~1A~ serotonin and D~2~ dopamine receptors were identified as such 25 years ago ([@bib15]; [@bib23]). There is, however, one notable and conspicuous exception: the odorant receptors (ORs). ORs comprise nearly 50% of the ∼800 GPCRs in humans, yet ∼90% of human ORs remain orphan receptors with unknown ligands. This is surprising when you consider that more than half of all non-olfactory GPCRs have been deorphaned to date. Furthermore, unlike most non-olfactory GPCRs, our olfactory perceptual experience means deorphanization strategies for ORs are not necessarily burdened by a lack of knowledge of relevant ligands ([@bib18]). The molecular mechanisms of OR activity have also been well described (e.g., [@bib25]). It is unlikely that fundamental differences in molecular function are the bottleneck in OR deorphanization, as ORs appear to use the same basic molecular mechanisms as other class A GPCRs in terms of ligand binding and transduction ([@bib11]; [@bib27]). Regardless, ORs are "poorly behaved" when it comes to functional assays.

Yet large-scale OR deorphanization is needed to elucidate basic principles of odor coding. Deorphanization will allow investigators to probe how OR activity is influenced by specific physicochemical properties of odorant molecules (i.e., develop odorant structure--activity relationships) and ultimately how this information is processed in the brain to elicit an "odor image" that can influence human or animal behavior by providing information on such aspects as perceived odor intensity, odor detection threshold, and valence. As Jerome Lettvin so eloquently and simply put it for the visual system with his seminal 1959 paper "What the Frog's Eye Tells the Frog's Brain," the olfactory field must first know "what the nose knows" to understand what it tells the brain ([@bib57]). This Review focuses on recent advances in OR deorphanization, from both the standpoint of receptor expression and that of ligand assay panel selection, highlighting some of the caveats that abound in this continuing but challenging endeavor.

Methods of deorphanization
==========================

Deorphanization using olfactory sensory neurons (OSNs).
-------------------------------------------------------

The most significant impediment to deorphaning an OR of interest has been the lack of a suitable cell-based heterologous expression system. The first three assays discussed circumvent this block by exploiting the OSN itself as the expression system. Using OSNs decreases the difficulty of expressing functional exogenous ORs because the cellular machinery, whatever that may be, is already poised to process ORs. Moreover, the receptive field of the OR (that is, the set of ligands capable of activating the OR and the relative potency of such ligands) is presumed to be of high fidelity because the OR is coupled to its native transduction cascade. There are tradeoffs in terms of the difficulty of the methodology and the throughput rate, but the techniques of adenoviral infection, gene targeting, and imaging of the dorsal olfactory bulb (OB) have added substantially to our knowledge of select ORs.

The earliest approach to studying a defined OR was to use a recombinant adenovirus to deliver exogenous genes into OSNs ([@bib120]; [@bib107]). In this approach, the virus is constructed with a constitutively active promoter that drives overexpression of an OR and a green fluorescent protein (GFP) marker. An internal ribosome entry site (IRES) sequence sandwiched between the exogenous OR and GFP produces the receptor and GFP as separate proteins in infected cells ([@bib86]). Introducing exogenous ORs into a native cellular environment permits proper trafficking and expression of untagged, unmodified receptors on the plasma membrane. Using the adenoviral technique, ligands for rat OR-I7---the first OR to be deorphaned---were discovered by recording OR activity ex vivo, using an electro-olfactogram (a moderate throughput screening methodology in which odorants are delivered in vapor phase to the intact olfactory epithelium) ([@bib120]). The adenoviral technique, coupled to calcium imaging of infected OSNs from dissociated olfactory epithelium (a low throughput ex vivo screening methodology in which odorants are delivered in aqueous phase to dispersed cells), was also used to confirm a ligand for mouse MOR23 ([@bib107]).

Gene-targeting strategies in mice provide another way to deorphan ORs in their native cell type. In this approach, a fluorescent marker protein sequence is inserted adjacent to the endogenous locus of a specific OR. Once again, an IRES sequence is used to mark cells expressing the particular OR. Like the adenoviral approach, the OR being gene targeted is typically left untagged and unmodified. But unlike the adenovirus approach, in which the exogenous and endogenous ORs are coexpressed in the same OSN, the gene-targeting approach permits expression of only the single OR. Two highly related mouse ORs, M71 and M72, with 96% amino acid identity, were deorphaned through gene targeting, using ex vivo calcium imaging of labeled M71 or M72 OSNs from dissociated olfactory epithelia ([@bib13]; [@bib24]).

Fully in vivo expression systems for ORs in OSNs have now been developed by coupling gene-targeting and OB recording techniques. This allows for realistic vapor-phase odorant delivery where the presence of mucus is preserved and odorants can be delivered under physiological conditions. The olfactory system is kept intact, from cell--cell contacts in the olfactory epithelium all the way to axonal projections to the brain. Further, odorants are delivered in the vapor phase. Although it is difficult to know the precise concentration and even the final form of an odorant that reaches the olfactory neurons because of the influence of an air--water or mucus interphase ([@bib79]), vapor-phase delivery provides a more realistic physicochemical environment. In contrast, in vitro and ex vivo (e.g., calcium imaging of dissociated olfactory epithelium) assays typically require odorants to be delivered in the water phase. Although water-phase odorant delivery may not exactly recapitulate the native physicochemical environment, it does allow for more accurate assessment of the concentrations of odorant delivered. Indeed, even higher odorant concentrations may be achieved in the water phase depending on the vapor pressure of the odorant. This may be one reason for the observed discrepancies in receptor profiles observed across the different assay systems (see below; [@bib83]). Thus, although a particularly technically challenging technique, in vivo assays provide the most realistic albeit perhaps a less well defined olfactory environment in which to perform functional studies.

The in vivo recording method takes advantage of the stereotyped topography of OSN projections between the olfactory epithelium and the OB. Sensory neurons expressing a specific OR coalesce in roughly two stereotyped locations of the OB called glomeruli, one located laterally and one medially ([@bib89]; [@bib111]; [@bib78]). These neuropil conglomerates are composed largely of the axons of OSNs synapsing onto dendrites of mitral and tufted neurons, with these second-order neurons then projecting axons forward to cortical regions of the brain ([@bib31]; [@bib98]; [@bib28]). Glomeruli located on the dorsal surface of the OB are accessible with minimal surgical manipulation, making them amenable to in vivo optical imaging recordings of OSN activity. Several imaging techniques have been used in the dorsal bulb to detect odorant-induced activity of OSNs of unknown OR identity. These include recording intrinsic signals ([@bib90]; [@bib109]), using the genetically encoded activity marker synapto-pHluorin ([@bib14]), applying calcium-indicator dyes ([@bib83]), and using optogenetic reporters for calcium and membrane voltage (Storace, D.A., L.B. Cohen, and U. Sung. 2013. Association for Chemoreception Sciences Annual Meeting. Abstr. P109). Although beneficial as an in vivo technique, imaging the dorsal surface of the OB only provides a partial picture of receptor activity because it can only report on the subset of OSNs that project to the dorsal glomeruli. Although receptor activity has been recorded from other areas of the OB ([@bib36]; [@bib99]), this requires substantial surgical manipulation and still suffers from sampling only a small subpopulation of receptor types.

More recently, specific ORs have been gene targeted so that identified ORs can be screened in the dorsal OB ([@bib9]; [@bib13]). Here, a fluorescent marker (e.g., tauGFP) is inserted in the locus just downstream of an OR that directs axons to the dorsal OB (such as M71). The resultant GFP-labeled glomerulus for that specific OR can thus be identified while functional activity can be viewed using intrinsic activity or a fluorescent activity indicator of a different wavelength. An extension of this technique expands the range of ORs that can be tested by replacing the dorsal bulb--targeting OR sequences with OR sequences that would normally direct axons elsewhere (as in the I7→M71 locus swap). The OSNs that express the replacement OR now form glomeruli located in the dorsal OB and are therefore amenable to dorsal OB imaging techniques ([@bib104]; [@bib108]). This gene-targeted approach in which dorsal-projecting OR loci are replaced by presumably any target OR sequence currently allows for the highest throughput of ligand screening among OSN-based systems, and it also allows odorants to be screened in the more physiological vapor phase. However, producing such a mouse line is both expensive and slow.

Contributions from OSN expression systems.
------------------------------------------

Native expression systems, in which defined ORs are expressed in OSNs, have yielded important insights into fundamentals of the olfactory code. Rat OR-I7 and mouse M71/M72 provide good examples. OR-I7 has been screened with panels of diverse and panels of only subtly different chemicals, thus providing in-depth structure--activity relationship insight for this receptor ([@bib5]). The initial electro-olfactogram recordings from OR-I7 adenovirus-infected regions of the epithelium revealed that, among a diverse panel of 74 test odorants spanning multiple chemical functional groups, only saturated aliphatic *n*-aldehydes with simple backbone chains of 7--10 carbons activated OR-I7. Within this range, the eight-carbon octanal was the most potent. Octanal was then used as the lead compound in a further electro-olfactogram screen in which a medicinal chemistry approach was undertaken. 90 different compounds with subtle and systematic changes in functional group, carbon chain length, degree of saturation, and type of side-chain substitution were tested ([@bib5]). This screen revealed that OR-I7 could tolerate particular patterns of unsaturation and branching but not others. This work provided the first thorough characterization of an OR's molecular receptive field and identified citral, a partial agonist of OR-I7, as the first known modulator of any OR's activity.

Screening OSNs from M71 or M72 IRES tauGFP gene-targeted animals ([@bib13]; [@bib24]) provided an opportunity to investigate how closely related receptors parse odorants. These receptors differ by only 11 amino acids. In initial calcium imaging of labeled OSNs from dissociated olfactory epithelia, the two ORs both seemed narrowly tuned to acetophenone. However, later patch-clamp recordings from the dendritic knobs of labeled OSNs revealed several receptor-discriminating ligands from among a large screen of 330 compounds ([@bib117]). How minor changes in OR amino acid composition can affect response profiles, and the implications for how confidently one can predict receptive fields based on overall sequence similarity, is an area open to active investigation.

Dose--response relationships (EC~50~s) of GFP-labeled M71 OSNs in the dissociated olfactory epithelium preparations display a surprising level of variability. For instance, the EC~50~ for acetophenone differed by more than an order of magnitude in different experiments ([@bib13]). This variability is also evident in ex vivo patch recordings of intact epithelia, as seen in the response of the mouse MOR23 receptor to Lyral ([@bib30]), suggesting that it is not merely a consequence of the dissociation method. Thus, it may be an inherent biological property of OSNs. Although this phenomenon has yet to be explored in in vivo systems, such biological variability calls into question how odorant concentration is encoded when OSNs expressing the same OR can nevertheless have quite different sensitivities.

An important aspect to consider when comparing multiple expression systems is fidelity, and the OSN-based expression systems show good cross-validation. In vivo functional imaging of GFP-labeled OR-I7 glomeruli ([@bib9]) has confirmed ex vivo electro-olfactogram and OSN calcium imaging results that indicate octanal is a potent OR-I7 ligand.

Deorphanization using heterologous expression systems.
------------------------------------------------------

Although they most faithfully recapitulate the receptive field, OSN-based expression systems are relatively low throughput. Moreover, they have been the principal mode of extended investigation for only seven ORs: rat OR-I7 ([@bib120]), mouse OR-I7 ([@bib13]), MOR23 ([@bib107]), MOR-EG ([@bib40]), MOR-EV ([@bib40]), M71 ([@bib13]), and M72 ([@bib24]). Although the main goal of high throughput compound screening is to identify more comprehensively the set of odorants that make up a given OR's receptive field, in time this process can lead to a compendium of ORs that share a given ligand ([@bib68]; [@bib106]; [@bib50]; [@bib87]). Large scale, heterologous-based screening thus holds the promise of providing a more substantive window onto the olfactory combinatorial code.

A particularly challenging problem, however, is that many ORs are retained in the ER of heterologous cells. Failing to traffic to the cell surface, the ORs are unable to interact with the odorant ([@bib64], [@bib65]). Models of a two-step process of intracellular OR trafficking in OSNs tend to focus primarily on the role of OSN-specific forward trafficking proteins ([@bib72]). These include assistive proteins such as receptor-transporting protein (RTP)1, RTP2, and receptor expression--enhancing protein (REEP)1 ([@bib91]), and certain non-olfactory GPCRs that may act as heterodimer partners ([@bib16]). One relatively unexplored possibility, however, is the inverse scenario in which heterologous cells possess or overexpress one or more negative trafficking factor(s). Such factors may retain ORs in the ER because of protein misfolding or because they fail to recognize even a properly folded OR as appropriate export cargo. In support of this possibility, ER retention by the organelle's quality control machinery has been documented for several non-olfactory GPCRs ([@bib49]; [@bib21]; [@bib110]). The OR trafficking complex in the OSN may thus involve the presence of OSN-specific forward trafficking factors or the absence of specific ER quality-control genes, both of which are largely unknown. A more thorough understanding of the apparently unique protein trafficking environment in OSNs could suggest modifications to help alleviate the bottleneck of functional OR expression in heterologous cells.

Some modified cell lines do provide an acceptable environment for functionally expressing at least certain ORs. Although systems such as *Xenopus* *laevis* oocytes ([@bib42]; [@bib1], [@bib2]), the insect Sf9 cell line ([@bib71]), yeast ([@bib75]), even budding baculovirus ([@bib76]) have been used, the mainstay of deorphanization through heterologous expression has been two human cell lines, HEK293 and HeLa ([Fig. 1](#fig1){ref-type="fig"}). HEK293 has been a reliable vehicle for studying mOR-EG ([@bib40]; [@bib42], [@bib43]; [@bib81],[@bib82], [@bib83]; [@bib7]), making mOR-EG a staple receptor for pharmacology studies and comparison with other heterologous expression systems. mOR-EG was identified through single-cell RT-PCR ([@bib40]) of eugenol-responding OSNs from dissociated mouse olfactory epithelia. Rather strikingly (in retrospect), mOR-EG could be functionally expressed directly in HEK293 cells, without cofactors or even an N-terminal tag on the OR. Although a non-olfactory G protein, G~α15~, is the OR coupling partner in HEK293 systems, mOR-EG still responded to the same ligands in the in vitro assay as those identified in the original ex vivo OSN screening ([@bib40]). HEK293 cells have also been used to express the human ORs hOR17-4 ([@bib105]), hOR17-40 ([@bib115]), and OR51E2 ([@bib97]), as well as the rat OR-I7 ([@bib51]), and the mouse ORs OR-I7 ([@bib51]) and Olfr78 ([@bib97]), although some of these latter cases involved the addition of a tag or leader peptide sequence to the N terminus of the OR sequence.

![OR signal transduction and functional readout of the main in vitro assay systems (A--C) and ex vivo dissociated OSNs (D). Salient differences between these assays include the use of N-terminal amino acid tags (e.g., Rho) and trafficking proteins (e.g., RTP1S) to promote cell surface expression, Gα~olf~ or Gα~15~ G proteins that trigger calcium ion (Ca^2+^) flux or cAMP production upon ligand binding, and Ric8b or myristoylated Ric8B (mRic8b) proteins that attenuate G protein signaling. RTP2 and REEP are present in Hana3A cells but appear to only marginally improve functional OR expression. RTP1S, REEP, and Ric8b mRNAs are expressed in OSNs, but there is a paucity of evidence for their function there. ACIII, adenylyl cylcase type III; ANO2, anoctamin 2 calcium-activated chloride channel; CNGA2, cyclic nucleotide--gated ion channel A2; CRE, cAMP response element; Luc, luciferase protein; OR, odorant receptor.](JGP_201311151_Fig1){#fig1}

The most common functional readout for ORs expressed in HEK293T cells coupled to G~α15~ is an intracellular increase in calcium, monitored using fluorescent calcium-binding dyes such as fura-2. This enables a fast readout, as the aqueous-delivered odorants only need to be applied transiently. But because odorants are typically applied sequentially (as opposed to concurrent application using a fluorescent imaging plate reader \[FLIPR\] assay, as will be discussed later), the overall time course of the experiment is prolonged and only a limited number of odorants can be tested on the same cell preparation. Such imaging thus represents only a low to mid-throughput approach.

The most widely used in vitro OR assay uses the Hana3A cell line, an extensively engineered system derived from HEK293T cells ([@bib91]). The Hana3A cell line stably expresses the canonical OSN G protein α subunit G~αolf~, bringing the signal coupling closer to an in vivo situation. Hana3A also stably expresses three OSN OR trafficking cofactors (RTP1, RTP2, and REEP) that have been shown to enhance cell surface expression of a subset of tested ORs ([@bib91]). In addition, coexpression of an alternative splice variant of RTP1 called RTP1S ([@bib116]), the guanine nucleotide exchange factor Ric8B ([@bib112], [@bib113]; [@bib46]), and the type 3 muscarinic acetylcholine receptor ([@bib60]) indicates that all three appear to work synergistically to enhance OR functionality without altering ligand specificity ([@bib121]).

In addition to this collection of cofactors, optimal cell surface expression often requires modification of the OR itself. In the Hana3A system, as in nearly all other in vitro OR assays, fusing the first 20 amino acids of rhodopsin (Rho tag) or other short noncleavable tags (e.g., Flag, c-myc, or HA) to the receptor's N terminus is common and typically necessary for optimal functional expression. But it is possible that such permanent tags modify OR response profiles ([@bib121]). Recently, a cleavable 17--amino acid leucine-rich N-terminal signal peptide (Lucy tag) was shown to promote cell surface OR expression in HEK293T cells ([@bib97]). The Lucy tag appears to operate synergistically with RTP1S, Ric8b, and a Flag-Rho tag. Strikingly, all 15 of the ORs tested with Lucy could be visualized on the cell surface by immunostaining. The use of cleavable tags like Lucy, where little or no tag remains on the mature OR, should help improve the in vivo relevance of screening data derived from in vitro systems.

The functional readout from Hana3A-based systems comes from pairing Gα~olf~ to an endogenously expressed adenylate cyclase to yield odorant-induced cAMP production. The increase in cAMP is monitored via a cAMP response element (CRE)-driven luciferase reporter, yielding light as the output ([@bib42]; [@bib91]). A potential drawback, however, is that when used with a standard luminometer plate reader, measurable and consistent odorant-dependent luciferase production in the CRE luciferase assay can require up to four hours of odorant stimulation. The potential for OR adaptation during such prolonged odorant exposure is unknown.

An alternative to these two main HEK293T-based systems is the HeLa/Olf expression system. This has been used successfully to deorphan ORs without added trafficking cofactors, although an N-terminal Rho tag on the OR is still typically used ([@bib100]). The HeLa/Olf system includes G~αolf~ and an adenylate cyclase like Hana-3A but differs in its functional readout. For the HeLa/Olf system, the odorant-induced cAMP activates an exogenously expressed variant of the CNG channel (CNGA2). cAMP binding to CNGA2 stimulates calcium influx, which can be detected using a fluorescent calcium--sensitive dye (e.g., Calcium 5). This calcium change could, in theory, be monitored for sequential applications of odorants as in the HEK assay. But in investigations using HeLa/Olf, the primary strategy has instead been to record receptor activity in real time with a FLIPR. FLIPR assays, which can be run in a multi-well format, are a widely used strategy for high throughput screening of GPCRs in the pharmaceutical industry ([@bib22]). The HeLa/Olf system thus allows for reduced odorant exposure times compared with luciferase reporter systems.

Caveats of heterologous expression systems.
-------------------------------------------

Heterologous expression systems have enabled the deorphanization and extended characterization of ∼95 mouse and 41 human ORs ([@bib67]) as of the beginning of 2014. Although still this means that only ∼8 and ∼10% of each species' OR repertoire, respectively, have been deorphaned, this contribution by in vitro studies stands in marked contrast to the mere seven ORs primarily studied using OSN-based methods and confirmed in separate studies over this same period (i.e., rat OR-I7 \[[@bib120]\], mouse OR-I7 \[[@bib13]\], MOR23 \[[@bib107]\], MOR-EG \[[@bib40]\], MOR-EV \[[@bib40]\], M71 \[[@bib13]\], and M72 \[[@bib24]\]). Thus, heterologous expression assays are the undisputed primary drivers of deorphanization. But several cautionary cases of assay-dependent bias should be considered when interpreting OR response profiles obtained in vitro.

One cautionary case involves the G protein identity. Some GPCRs can couple with more than one G protein α subunit. Recent evidence suggests that when a given GPCR is docked to a particular G protein α subunit, a certain subset of chemicals may serve as ligands, but when docked to an alternate G protein α subunit, the functional set of ligands may change. Thus, some ligands preferentially signal through a particular pathway ([@bib103]). Such stimulus signaling bias has been reported for ORs in heterologous systems and can alter the resulting odorant response profile ([@bib100]; [@bib83]; [@bib34]). [@bib100] showed that the noncanonical G~α15~, the G protein commonly used in HEK-based systems, can alter the odorant specificities and pharmacological profile of ORs. For example, when ORs6 was coupled to G~α15~, octanoic acid was an agonist. But when ORs6 was coupled to G~αolf~, octanoic acid not only failed to activate the receptor, but it actually served as a competitive antagonist. The same study by [@bib100] also illustrated how the G~α15~ G protein displays "permissiveness"; 7 of the 14 ligands for mouse receptor olfr43 were agonists in only the G~α15~ but not the G~αolf~ background, suggesting that G~α15~ may enable more indiscriminate ligand binding. Although G~α15~ assays may thus provide a good measure of ligand-binding potential, they may not reveal the whole story with regard to receptor function. Ligand efficacy, which includes the activity of the entire receptor--G protein complex and downstream signaling cascade, is a more relevant measure of receptor activity. This suggests that assays involving the canonical G protein, G~αolf~, may more accurately measure ligand efficacy and may therefore provide a better gauge of the OR's discriminatory capacity. Although the inconsistencies depending on coupling agent make comparisons across studies difficult, they may lead us to a better understanding of how the G protein--OR complex acts as a unit in determining OR receptive fields.

Although the influence of the assay on the reported receptive fields has been documented for rat OR-I7, ([@bib77]), MOR29B ([@bib108]), and the trace amine-associated receptor TAAR4 ([@bib118]), this bias has been most thoroughly explored for mOR-EG ([Fig. 2](#fig2){ref-type="fig"}). [@bib83] compared the specificity and sensitivity of the mOR-EG response profile in vitro in HEK293 cells coupled to either G~α15~ or G~αolf~, ex vivo by calcium imaging of OSNs from the dissociated olfactory epithelium of a mOR-EG--labeled transgenic mouse, and in vivo by intrinsic imaging of GFP-labeled glomeruli in this same transgenic mouse line. The response profile of mOR-EG to seven odorants in HEK293 and dissociated OSNs was nearly identical, although some difference was observed depending on the G protein used in the HEK293 assay. In particular, the downstream coupling partner affected the ability of isoeugenol to serve as an agonist. But the most unexpected results came from the in vivo assay. Vanillin and 4H3MBA, delivered in water phase, were strong mOR-EG agonists in both HEK293 cells coexpressing G~αolf~ and dissociated OSNs (which also express G~αolf~). Yet when OSN activity was measured in the vapor phase at the level of the glomeruli, very modest or no responses to these odorants was obtained. This was not caused by a general decrease in sensitivity in the in vivo method of recording. Indeed, an ∼1,000 times increase in the sensitivity to eugenol was observed with in vivo glomerular imaging compared with the other assay systems. Intriguingly, the responses of mOR-EG glomeruli to vanillin before and after washout of the nasal cavity suggest that the olfactory mucus may account for part of the observed difference. Thus, caution extends even to ex vivo work with OSNs from dissociated olfactory epithelia; the presence of mucus and a fully intact in vivo system may better define the physiologically relevant boundaries of a receptive field. But until it is resolved how odorants may partition into the mucus, and how this affects their effective concentration, a continued benefit of ex vivo work is that the aqueous concentrations can be well controlled. This in turn provides an accurate view of which odorants can bind a given OR and enables the development of structure--activity relationships.

![Response profiles of rat OR-I7 and mouse OR-EG expressed in various assay systems. The response profiles of a given OR can vary depending on the assay system. For rat OR-I7 and mouse mOR-EG, tested but inactive compounds are not included in this figure unless the compound showed agonist or antagonist activity in at least one of the assays shown. For rat OR-I7, only select agonists are reported. See [@bib5] for a more complete listing of OR-I7 agonists. Blue boxes, heat map of reported EC~50~ values; darkest blue, \<0.1 µM; lightest blue, 660 µM; black boxes, agonist but no EC~50~ reported; orange boxes, partial agonist; red boxes, antagonist; white boxes, tested but inactive; Int, intrinsic imaging; Ca^2+^, calcium imaging; I, current; luc, luciferase; Seap, secreted alkaline phosphatase; OB, olfactory bulb; OSN, olfactory sensory neuron; COS, African green monkey cells; Ocy, *Xenopus* oocytes; H3A, Hana3A cells; HEK, human embryonic kidney cells. References: 1, [@bib9]; 2, [@bib6]; 3, [@bib85]; 4, [@bib52]; 5, [@bib58]; 6, [@bib13]; 7, [@bib83]; 8, [@bib88]; 9, [@bib121]; 10, [@bib7]; 11, [@bib43]; 12, [@bib81],[@bib82]).](JGP_201311151_Fig2){#fig2}

Contributions from heterologous expression systems.
---------------------------------------------------

Despite these caveats, the throughput capacity of heterologously expressed ORs offers a valuable window to OR biology. For example, mOR-EG's extensive characterization in the HEK293 system ([@bib42], [@bib43]; [@bib81],[@bib82]) and the ability to readily express even mutated mOR-EG receptors ([@bib43]; [@bib44]) paved the way for detailed analysis of the relationship between agonist and antagonist ligands. From screening with blends, the odorants methyl isoeugenol, isosafrole, and dimerized isoeugenol were identified as antagonists of mOR-EG as expressed in HEK293 cells with G~α15~ ([@bib81],[@bib82]). These results, along with trends among identified agonists and antagonists for other ORs ([@bib5]; [@bib93]; [@bib100]; [@bib38]; [@bib2]; [@bib85]), suggest that most OR antagonists are likely to be structurally related to the agonist compounds, be odorants themselves, and exhibit competitive antagonism. But it was through a large structure--activity relationship study coupled with point mutagenesis that a mechanism for antagonism in mOR-EG was proposed and tested ([@bib43]). Vanillin, a potent agonist, was used as the lead compound in a medicinal chemistry approach that varied the substituents around three positions of vanillin's benzene ring. 21 additional compounds were screened and 13 were found to activate mOR-EG over a 100-fold span in relative affinity (EC~50~), starting in the low micromolar range. By combining these structure--activity relationship results with the results from point mutations and computational homology modeling, the mOR-EG odorant-binding site was predicted. It consisted of a hydrophobic pocket formed by portions of transmembrane domains III, V, and VI. Nine amino acids within the presumptive binding pocket were shown to be involved in receptor activation. They propose that there are critical electronic interactions between a phenyl ring in the binding pocket and the particular double-bond pattern in the tail of isoeugenol and related antagonists. A simple shift of the double bond by one position was sufficient to turn an isoeugenol-like antagonist into a eugenol-like agonist. Thus, this electrostatic interaction between ligand and receptor may be the switch that filters agonists from antagonists for this OR.

Heterologous expression systems can also provide deep insight about the combinatorial code, as is evident in the work of [@bib92]. Using the Hana3A cell-line approach, this group produced the largest single dataset to date, in which 93 odorants, spanning a large portion of the chemical space of commercially available odorants, were tested on 62 ORs. The authors then determined the potency of each of the 63 odorants that activated at least one OR. The resulting information-dense matrix revealed intriguing and unexpected coactivation patterns by odorants both across ORs and within the receptive field of individual ORs. Because these ORs are heterologously expressed, these patterns can be probed further. The ability to devise hypotheses about chemical relationships and then revisit the same ORs, to test them with a new panel of compounds, is a great strength of heterologous expression systems.

In silico approaches to deorphanization
=======================================

The challenges of expressing ORs on the cell surface and of probing them with very large numbers of ligands make computational in silico approaches an attractive alternative for deorphaning ORs. A robust in silico system could conceivably allow virtual high throughput screening of all compounds that possess physicochemical features that make them likely odorants. This would provide a substantial dataset from which to develop a detailed pharmacophore model of the chemical features and their arrangement that is required for activation of the OR in question. A glimpse of such potential was seen for the in vitro deorphaned OR1G1, which was activated by 59 of 95 diverse odorants ([@bib93]). Having such a large agonist repertoire allowed derivation of the best-defined pharmacophore for an OR to date ([@bib94]). In silico approaches that build up large datasets of predicted binders and nonbinders may thus help identify the true feature detector capabilities of each OR.

One major in silico approach that lends itself to receptor deorphanization is to construct OR models and dock potential ligands ([@bib102]; [@bib101]; [@bib33]; [@bib35]; [@bib43]; [@bib53], [@bib54], [@bib55]; [@bib2]; [@bib96]; [@bib52]; [@bib4]; [@bib7]; [@bib17]; [@bib26]; [@bib56]). OR modeling has typically worked in close concert with a biologically expressed OR, with deorphaning of the OR in the biological expression system preceding development and refinement of an in silico model. Models have primarily been used to help direct site mutagenesis studies, propose rationale for ligand discrimination, and address other questions of receptor biology versus serving as a stand-alone screening system. On the rare occasions where OR models have been used to try to predict novel ligands for a given OR, success rates have been mixed. [@bib33] built two models of the rat OR-I7 receptor, into which 62 putative ligands were docked and their predicted binding energy was calculated. A high binding energy should correlate with empirical binding. In their first build, no molecule had a binding energy of 30 kcal/mol or higher. When [@bib33] refined their model-building procedure, they now found odorants that bound in the 30-kcal/mol range, 69% of which were later empirically confirmed to be activating ligands. In silico screening of libraries of ligands has recently seen a resurgence. For MOR42-3, 40 candidates were selected from an initial 574 odorant panel based on docking to a receptor model; 55% of these high scorers were validated in a physiological screen ([@bib8]). Dynamic modeling has also brought improvements to in silico screening systems, correctly predicting the binding of amyl butyrate to hOR2AG1 and mOR283-2 ([@bib26]).

ODORactor, a web-based tool, takes a quite different approach to in silico--assisted deorphanization ([@bib63]). OR models approach the combinatorial code from the "one OR is activated by multiple odorants" facet. ODORactor approaches the code from the "one odorant activates multiple ORs" facet, making in silico predictions of the suite of ORs that detect a given ligand. Eschewing model building, ODORactor has data-mined all published deorphaned human and mouse ORs and uses multidimensional analysis and chemoinformatics in its predictions. ODORactor may prove to be a valuable tool when the odorant is of special interest, such as for potential pheromones or other behavior-modulating chemicals ([@bib61]), or odorants of practical ([@bib19]; [@bib59]) or commercial relevance ([@bib10]).

Caveats to in silico approaches.
--------------------------------

Although in silico approaches show promise, at present they still benefit from validation by biological means. Some of the challenges still to be surmounted by the modeling approach are evident in work on rat OR-I7. Rat OR-I7 has been modeled independently for over a decade ([@bib101]; [@bib33]; [@bib53]; [@bib47]; [@bib52]) using various technical approaches. However, only one residue is consistently implicated in binding octanal; the remaining residues predicted to line the binding pocket are highly contested. Alignment of ORs to a template GPCR is a key step in certain types of model building. Bovine rhodopsin in its retinal-bound, inactive state was at one time the only mammalian class A GPCR with 3-D structural information ([@bib84]). Even recent OR models still often use the rhodopsin template as part of the construction and optimization process. But now an array of other crystallized class A GPCRs in their active state are available. The GPCRautomodel web tool enables users to select among these new templates when building an OR model ([@bib56]). Whether new alignment choices lead to improved receptive field predictions remains to be seen.

Because ODORactor updates its database with each new publication, one thing to be mindful of is that its predictions are dependent on the sum quality of published data. For example, the predictions for mouse ORs made by the current version of ODORactor may be heavily weighted by the receptor and ligand profiles present in the in vitro heterologous expression work of [@bib92], given that this study contributes nearly half of all currently deorphaned mouse ORs. How ODORactor deals with conflict, given that the details of the receptive field for the same OR can vary depending on the readout system it is coupled to ([Fig. 2](#fig2){ref-type="fig"}), also needs to be considered. Finally (provided the OR can be expressed), although the positive hits predicted by ODORactor can be validated, the frequency of false negative predictions by ODORactor cannot be readily discerned. As more ORs outside the initial ODORactor build are deorphaned and compared with ODORactor predictions before and after publication, this will clarify the capabilities and constraints of this intriguing new tool.

Choosing ligands for deorphanization
====================================

Wide-scale screens with various rationale.
------------------------------------------

Once a given OR has been successfully expressed, there remains the question of how to look for that first activating ligand in vast chemical space. One possibility involves a "shotgun" approach where many odorants are simply tried either alone or in blends without clearly disclosed rationale. Testing blends followed by fractionation would seem the obvious choice to increase the number of odorants screened. But there can be concerns about solvent levels in multiple-component blends. Furthermore, this technique can backfire should an antagonist be present in the same fraction as an agonist. Given that many of the currently published antagonists are structurally similar to agonists of the same receptor ([@bib5]; [@bib81],[@bib82]; [@bib93]; [@bib100]; [@bib38]; [@bib2]; [@bib85]), blends that contain related odorants may be at particular risk of generating false negatives in functional studies. However, interactions can still occur even among unexpected pairings. This was highlighted during the use of the Henkel100 blend to deorphan hOR17-4 ([@bib105]). The only agonist to emerge from the series of mixes was cyclamal. During the follow-up medicinal chemistry exploration, however, the closely related bourgeonal was found to be active even though the mix containing it had been inactive. By fractionating that mix, it was determined that the structurally unrelated undecanal was the culprit antagonist. Thus, although precautions can be taken to divide seemingly similar components into different mixes, the encoding of odorants by ORs is still not sufficiently understood to assure that mixes will not exhibit interaction effects.

One guide to shotgun-type approaches is the data emerging from calcium imaging of OSNs from dissociated olfactory epithelia of wild-type mice or rats. The identities of the ORs are not known in this method, but because the full OR repertoire is surveyed, this approach can provide useful population-level information of the relative activity elicited by a given odorant. Although ORs are expressed at different frequencies ([@bib48]), such that an odorant that activates many OSNs could conceivably be targeting just one or a few highly expressed ORs, constructing an odorant panel whose components each activate many OSNs with minimal overlap in their coverage remains a reasonable strategy for first-pass, general deorphanization of an OR. Although surveys using blends have shed light on OR repertoire coverage ([@bib80]), more commonly single odorants are used. Surveys with single odorants have highlighted important trends. For example, flexible odorants appear to activate more OSNs than do highly constrained ones ([@bib85]), flexible odorants with mid-length chains (between seven to nine carbon backbone) recruit more OSNs than do much shorter or longer ones ([@bib95]; [@bib41]; [@bib6]), and acids seem to be poor recruiters relative to alcohols or aldehydes of the same length ([@bib6]). Attentiveness to such trends during panel design may help maximize the potential for hits.

A second form of guidance can be found in the computational analysis of biologically relevant chemical space. This is the subset of all chemicals, such as those that can be found in larger databases such as PubChem or the Available Chemicals Directory, filtered based on general parameters that typify odorants. Chemical space is the multidimensional arrangement of these putative or known odorants based on their physicochemical descriptors and biological functional similarity. It is organized so that the displacement of two odorants relative to each other is related to the probability of their being co-detected by ORs (closer odorants being more likely to be co-detected). Determination of an appropriately weighted chemical space has helped generate highly accurate predictions of the receptive fields for the mosquito *Anopheles gambia* ([@bib114]) and the fruit fly *Drosophila melanogaster* ([@bib12]). Currently, there are three models for the chemical space as weighted using data from mammals ([@bib32]; [@bib92]; [@bib67]). To help navigate and use one model of this space, [@bib32] provided lists of common odorants that should comprise broadly dispersed initial screening panels. "Broad" here refers to the diameter of the hypersphere that encloses the odorants in multidimensional space. Models of chemical space are being used retroactively to assess the breadth of coverage of assay panels and the breadth of tuning of OR receptive fields ([@bib92]; [@bib59]). However, panels composed by this method have yet to be deployed for initial deorphanization attempts.

Targeted screens that take the receptor into account.
-----------------------------------------------------

The above approaches to identifying the first ligand emphasize chemical diversity, focusing solely on the odorants. In contrast, the paralogue/orthologue approach uses information about the receptor to guide selection of a set of odorants to test. Paralogues within a species often share elements of their receptive fields, such as seen with M71 and M72 (96% protein identity) ([@bib117]), and MOR29A and MOR29B (95% protein homology) ([@bib108]). But when using the paralogue approach to testing compounds that are successful ligands of the "reference" OR against the orphan OR, there is the chance that the reference OR might be narrowly tuned. The three members of the large MOR256 family provide a telling, cautionary example. Whereas MOR256-17 responds to a variety of ligands, MOR256-8 and MOR256-22 can detect only a restricted subset of the MOR256-17 receptive field. Furthermore, the receptive fields of MOR256-8 and MOR256-22 show very sparse overlap with each other ([@bib59]). Thus, in this case, which OR is chosen as the reference would greatly affect success in deorphaning even related receptors.

As an alternative to comparing paralogues, looking across species to a deorphaned orthologue is often more productive. Some orthologues with very similar receptive fields include mouse and rat OR-I7 ([@bib13]), and mouse Olfr43 and human OR1A1 and OR1A2 ([@bib96]). In a far-ranging survey of 17 rat ORs and their mouse orthologues and 18 chimpanzee ORs and their rhesus macaque orthologues, [@bib3] concluded that orthologues are nearly 2.5 times more likely to share a ligand in common than are paralogues. They also demonstrated that orthologues often share an extended ligand profile, albeit with differences in odorant EC~50~s. These findings should provide encouragement for those seeking to extend findings from mouse ORs to human ORs.

Although robust, the orthologue approach is limited to a handful of ORs because the OR to be deorphaned must be a specific match. This is opposed to the paralogue approach that requires only family affiliation and thus has greater widespread applicability for deorphaning. But why might comparing paralogues not be as good a predictor in terms of similarity of receptive fields as when orthologues are compared? One contributing factor may be that the current classification of ORs into families is hierarchical in nature and based on full-length sequence. A reorganization based on short motifs with predicted functional relevance may improve performance. The foundations for alternative organizations already exist. Two studies independently identified short motifs distributed throughout the OR ([@bib62]; [@bib119]). [@bib70] compared select mouse and human orthologues and paralogues to identify a set of 22--amino acid residues, predicted to have special impact on ligand recognition. [@bib92] identified 15 residues for which 16 optimized physicochemical property descriptors were very good at predicting the response of 62 ORs to a panel of 63 odorants. Any of these motif lists can be used to break free of hierarchical constraints and plot ORs in multidimensional space. The resultant new relationships between ORs may better incorporate known or inferred physiology.

Beyond deorphanization: Integration with the combinatorial code
===============================================================

When a ligand has been found for the expressed OR of interest, a common next step is to use a medicinal chemistry approach to look for additional ligands to help characterize the structure--activity relationship for that OR. For example, a battery of compounds with subtle changes may be used to examine the discriminatory capacity of the receptor. This approach has been used successfully for many receptors, including mOR-EG ([@bib43]) and M72 ([@bib117]). Both receptors were tested with panels of small aromatics. Because only compounds with scaffolds similar to the initial target are tested, there may be a tendency to consider that a receptor is "narrowly tuned." But expanding to more diversified test panels can sometimes yield a marked shift in perspective. For example, [@bib7] tested an assortment of odorants on mOR-EG, and [@bib104] tested a collection of compounds on M72. In neither case did these ORs appear to remain so "narrowly tuned"; mOR-EG also responded to aliphatic cyclic ketones and M72 to aliphatic tiglate esters. It can be daunting to probe OR recognition of structurally diverse odorants because such a search is likely to return many inactive compounds. But this type of expanded testing provides valuable information to challenge pharmacophore models. This, in turn, can better clarify what chemical features the OR truly abstracts.

Another strategy to expand beyond an initial lead compound is to challenge the OR with odorants that the larger OR repertoire reports as "biologically similar." This strategy can apply to subsections of the odorants as well, as in the case of substituting a cyclohexene ring in place of a benzene ring. Such odorants may appear structurally dissimilar, but as the exchanges proposed are empirically based, the approach may be particularly productive. The information on "biological similarity" can be gained from calcium imaging of OSNs from dissociated olfactory epithelia of wild-type mice or rats. Even though the identity of the ORs is not known, the large-scale patterns across the OR repertoire show how frequently two odorants are recognized by the same OSN. This information can be used to generate probability tables. Such tables may aid deorphaning efforts by suggesting what other odorants are likely activators. Knowledge of expected co-recognition rates can also flag when an OR is making a challenging discrimination, thus contributing in a special way to the combinatorial code.

Future perspective
==================

A relatively new approach to deorphanizing human ORs involves genomics, where the presence of naturally occurring genetic variations (single-nucleotide polymorphisms) in individual OR genes are correlated with the relative activities of the ORs in vitro and the measured odor perception in humans ([@bib45]; [@bib74]; [@bib66]; [@bib73]; [@bib39]; [@bib67]). This approach has been successful in correlating the activity of individual ORs with measureable perceptual characteristics like odor intensity and pleasantness ratings. These emergent genomics-based OR percept studies may represent a powerful new strategy for OR deorphanization because they can provide a direct link between OR identity and perception. However, inherent to this and all other OR deorphanization strategies is the absolute requirement for a robust in vitro assay to confirm putative ligand--receptor pairings and to probe odorant structure--activity relationships.

The need for a comprehensive OR assay platform that balances throughput and response accuracy is thus critical for understanding the olfactory combinatorial code. A more robust in vitro platform ([Fig. 3](#fig3){ref-type="fig"}) could enable the identification and expression of all ORs contributing to the combinatorial activation code for an odorant or odor mixture ([@bib69]). The need for such a platform is especially pronounced given that ligands for ∼90% of human ORs remain unknown. Various techniques have been adopted including using native OSNs and an array of heterologous expression systems. But each of these systems has inherent strengths and limitations, and none have all the desired criteria of a suitable assay platform. For now, the optimal screening platform should encompass an initial high throughput chemical screen using in vitro heterologous systems followed by a low throughput in vivo assay for validation. Perhaps future implementation of interdisciplinary strategies that are routinely used by the pharmaceutical industry for the discovery of GPCR agonists and modulators ([@bib37]; [@bib20]) could contribute to more advanced and reliable heterologous OR systems.

![Schematic overview of a comprehensive OR assay platform and the approximate single assay compound throughput. Given the inherent complexity of the combinatorial receptor code and the remaining challenges of current in vitro OR assays, a comprehensive OR assay platform would aim to balance screening throughput and organism relevance by incorporating in vitro, ex vivo, and in vivo assays. A robust in vitro platform would enable the initial screening of thousands of odorant compounds. Agonists or antagonists identified from in vitro systems could then be screened using ex vivo OSN assays (medium throughout and relevance) or in vivo imaging assays (low throughput and high relevance). A salient benefit of in vivo over ex vivo or in vitro assays is that odorants are delivered in the vapor phase to the fully intact peripheral olfactory system (olfactory epithelium and bulb). The main benefit of ex vivo over in vitro assays is the use of OSNs as an expression system for native (i.e., untagged) receptors. OB, olfactory bulb; OE, olfactory epithelium; OSNs, olfactory sensory neurons; MU, olfactory mucus.](JGP_201311151_Fig3){#fig3}

Aside from the issue of proper trafficking, another reason for the relative paucity of deorphaned ORs may be that compounds used for screening have limited structural diversity and may not fully span odorant chemical space. This could be a matter of availability as commercial sources possess only limited collections of standard fragrance compounds. Moreover, commercial sources may not provide a sufficient range of subtly different odorants to serve as medicinal chemistry probes, particularly when the lead odorant has a rare or complex chemical scaffold. One relatively untapped source of both diverse and nuanced chemical libraries is the major flavor and fragrance houses. With more than 100 years of experience in chemical synthesis and purification, flavor and fragrance houses possess extraordinary collections of organoleptically defined volatile compounds that could greatly assist in both decoding the combinatorial code at the receptor level and help generate hypotheses of how that code correlates with percept. Olfactory research collaborations between academic and industry partners can be fruitful (e.g., [@bib29]) and should be strengthened further to provide greater access to diverse and well-characterized odorant libraries. Ultimately, such partnerships may be an important step forward in the quest to unravel the complex and often puzzling relationships between chemical structure, receptor activity, and human perception.
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